- Conditions
- Acute Myeloid Leukemia in Remission
- Interventions
- Azacitidine, Decitabine, Venetoclax
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
Recognized from query: venetoclax. Matching terms were moved into the structured fields above when recognized.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–465
of 465
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, AML, Adult
- Interventions
- evorpacept, venetoclax, azacitidine
- Drug
- Lead sponsor
- ALX Oncology Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
- Conditions
- Myeloproliferative Neoplasm
- Interventions
- Pacritinib, Venetoclax, Azacitidine, Magnetic Resonance Imaging, Computed Tomography, Bone Marrow Aspiration
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
- Interventions
- Iomab-B, Conventional Care, HCT
- Drug · Procedure
- Lead sponsor
- Actinium Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 22
- States / cities
- Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
- Conditions
- Acute Myeloid Leukemia, Pediatric AML
- Interventions
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia
- Interventions
- Ponatinib, Venetoclax, Mini-hyper CVD
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 28 more
- Conditions
- Leukemia, Myeloid Leukemia, Monocytic Leukemia
- Interventions
- Venetoclax, Azacitidine, Mitoxantrone
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Venetoclax
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 32
- States / cities
- Cerritos, California • Los Alamitos, California • San Luis Obispo, California + 28 more